ANTICANCER ACTIVE INGREDIENT DERIVED FROM GUIERA SENEGALENSIS

PROBLEM

One recognizes mainly in *Guiera senegalensis* the properties anti-inflammatory drugs, disinfectants, bechic, diuretic, eupneic and febrifuge. From where its regulation for cough, the states dyspneic, paludism, pneumopathies, the bronchopathies. In fact the sheets are generally used in the form of decocte or macerated in bath and like drink. In external use, *Guiera senegalensis* is regarded as vulnerary disinfectant, healing for the treatment of the wounds, the stomattites, gum diseases, of the chancres. A methoxylate naphtyl butenone, called Guieranone A, was isolated from the sheets of *Guiera senegalensis*. Guieranon A has Naphtyl Butenone from the Leaves of *Guiera senegalensis* with Antifungal Activity.

TECHNOLOGICAL SOLUTION

The inventors could isolate a new compound starting from *Guiera senegalensis*, Guieranon B. This new compound usable as pharmaceutical active ingredient, in particular in the treatment of cancer, and can be presented in the form of an extract of plant concentrated or in the form of composed of synthesis.

The inventors moreover discovered that this compound presents a high antiproliferative activity, as that was shown on line of cells cancerous mammary MCF-7. An object of the invention is thus to propose Guieranon B like new compound or pharmaceutical active ingredient, in particular like new anti-cancer agent.

APPLICATIONS

- For parenteral administration, intravenous routes in prostate, breast and colon cancers.

CURRENT STAGE OF DEVELOPMENT

- Maturation in progress

PATENT

FR2980196
WO2013037964

INVENTORS

Chalard Pierre, Caldefie-Chezet Florence, Delort Laetitia, Patel Kirti

LABORATORY

Human Nutrition Unit
Team: CELlular micro-Environmetry, Immunomodulation and Nutrition
VISIT US:

Institute of Chemistry of Clermont-Ferrand
Team: Design and Synthesis of Analgesic Molecules (CESMA)
VISIT US:

<table>
<thead>
<tr>
<th></th>
<th>C50 (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamoxifen</td>
<td>4.2 ± 4.24</td>
</tr>
<tr>
<td>5-FU</td>
<td>0.02 ± 0.25</td>
</tr>
<tr>
<td>Guieranon B</td>
<td>2.34 ± 0.13</td>
</tr>
</tbody>
</table>

This table below describes anti-proliferative activities for 3 different active principles (tamoxifène, 5-FU et Guieranone B), on the same breast cancerous cells MCF-7, with the same laboratory condition. The CISO (half maximal inhibitory concentration) observed for Guieranone B (7.09µM) is between tamoxifen and 5-FU values. Thus Guieranone B could be an interesting active principle for breast cancer treatment.

CONTACT: Business developer - Solène Vallin - solene.vallin@udamail.fr

© 2014 - Université Blaise Pascal

OPPORTUNITY: License and exploitation - Look for collaborative research

AVAILABLE FOR LICENSING